Characterization of APOE Christchurch carriers in 455,306 UK Biobank participants.
作者信息
He Karen Y, Khramtsova Ekaterina A, Cabrera-Socorro Alfredo, Zhang Yanfei, Li Shuwei, Sarver Brice A J, Smets Bart, Li Qingqin S, De Muynck Louis, Parrado Antonio R, Lovestone Simon, Black Mary Helen
机构信息
Population Analytics & Insights, Data Science Analytics & Insights, Janssen R&D, Spring House, PA, USA.
Neuroscience Therapeutic Area, Janssen R&D, Beerse, Belgium.
出版信息
Mol Neurodegener. 2023 Nov 28;18(1):92. doi: 10.1186/s13024-023-00684-7.
Abstract
摘要
相似文献
1
Characterization of APOE Christchurch carriers in 455,306 UK Biobank participants.对455306名英国生物银行参与者中APOE克赖斯特彻奇变异携带者的特征分析。
Mol Neurodegener. 2023 Nov 28;18(1):92. doi: 10.1186/s13024-023-00684-7.
2
Investigating the synergistic effects of hormone replacement therapy, apolipoprotein E and age on brain health in the UK Biobank.研究英国生物库中激素替代疗法、载脂蛋白 E 和年龄对大脑健康的协同作用。
Hum Brain Mapp. 2024 Feb 1;45(2):e26612. doi: 10.1002/hbm.26612.
3
Alzheimer disease genetic risk factor APOE e4 and cognitive abilities in 111,739 UK Biobank participants.111739名英国生物银行参与者中阿尔茨海默病遗传风险因素APOE e4与认知能力的关系
Age Ageing. 2016 Jul;45(4):511-7. doi: 10.1093/ageing/afw068. Epub 2016 Apr 21.
4
5
Alzheimer's Disease Susceptibility Gene Apolipoprotein E (APOE) and Blood Biomarkers in UK Biobank (N = 395,769).英国生物库中阿尔茨海默病易感性基因载脂蛋白 E（APOE）和血液生物标志物（N=395769）
J Alzheimers Dis. 2020;76(4):1541-1551. doi: 10.3233/JAD-200338.
6
Commentary: APOE e4 Genotype Predicts Severe COVID-19 in the UK Biobank Community Cohort.评论：APOE ε4基因型在英国生物银行社区队列中可预测严重的2019冠状病毒病。
Front Immunol. 2020 Sep 15;11:1939. doi: 10.3389/fimmu.2020.01939. eCollection 2020.
7
APOE targeting strategy in Alzheimer's disease: lessons learned from protective variants.阿尔茨海默病中的载脂蛋白E靶向策略：从保护性变体中吸取的经验教训。
Mol Neurodegener. 2022 Aug 3;17(1):51. doi: 10.1186/s13024-022-00556-6.
8
The Relationship Between Physical Activity and Non-Modifiable Risk Factors on Alzheimer's Disease and Brain Health Markers: A UK Biobank Study.体力活动与阿尔茨海默病和脑健康标志物的不可变风险因素之间的关系：一项英国生物银行研究。
J Alzheimers Dis. 2024;101(4):1029-1042. doi: 10.3233/JAD-240269.
9
APOE in Alzheimer's disease and neurodegeneration.阿尔茨海默病和神经退行性变中的载脂蛋白E
Neurobiol Dis. 2020 Jun;139:104847. doi: 10.1016/j.nbd.2020.104847. Epub 2020 Mar 21.
10
Influence of Western diet and APOE genotype on Alzheimer's disease risk.西方饮食和载脂蛋白E基因型对阿尔茨海默病风险的影响。
Neurobiol Dis. 2020 May;138:104790. doi: 10.1016/j.nbd.2020.104790. Epub 2020 Feb 4.
引用本文的文献
1
ApoE3 Christchurch and tau interaction as a protective mechanism against Alzheimer's disease.载脂蛋白E3克赖斯特彻奇型与tau蛋白的相互作用作为对抗阿尔茨海默病的一种保护机制。
Alzheimers Dement. 2025 Jul;21(7):e70396. doi: 10.1002/alz.70396.
2
Driving research on successful aging and neuroprotection in Latin America: Insights from the inaugural symposium on brain resilience and healthy longevity.推动拉丁美洲成功老龄化与神经保护研究：首届脑韧性与健康长寿研讨会的见解
Alzheimers Dement. 2025 Mar;21(3):e70037. doi: 10.1002/alz.70037.
3
UK Biobank-A Unique Resource for Discovery and Translation Research on Genetics and Neurologic Disease.英国生物银行——遗传学与神经疾病发现及转化研究的独特资源。
Neurol Genet. 2025 Jan 17;11(1):e200226. doi: 10.1212/NXG.0000000000200226. eCollection 2025 Feb.
4
Decreased lipidated ApoE-receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes.脂质化的载脂蛋白E（ApoE）与受体的相互作用减少，可保护细胞免受ApoE及其溶酶体中脂质成分致病性的影响。
Cell. 2025 Jan 9;188(1):187-206.e26. doi: 10.1016/j.cell.2024.10.027. Epub 2024 Nov 11.
5
Current insights into apolipoprotein E and the immune response in Alzheimer's disease.当前对载脂蛋白 E 与阿尔茨海默病免疫反应的认识。
Immunol Rev. 2024 Oct;327(1):43-52. doi: 10.1111/imr.13414. Epub 2024 Oct 24.
6
Multifaceted roles of APOE in Alzheimer disease.载脂蛋白E在阿尔茨海默病中的多方面作用。
Nat Rev Neurol. 2024 Aug;20(8):457-474. doi: 10.1038/s41582-024-00988-2. Epub 2024 Jun 21.
本文引用的文献
1
APOE targeting strategy in Alzheimer's disease: lessons learned from protective variants.阿尔茨海默病中的载脂蛋白E靶向策略：从保护性变体中吸取的经验教训。
Mol Neurodegener. 2022 Aug 3;17(1):51. doi: 10.1186/s13024-022-00556-6.
2
Rare APOE Missense Variants-Can We Overcome APOE ε4 and Alzheimer Disease Risk?罕见的载脂蛋白E错义变体——我们能否克服载脂蛋白Eε4与阿尔茨海默病风险？
JAMA Neurol. 2022 Jul 1;79(7):649-651. doi: 10.1001/jamaneurol.2022.0854.
3
New insights into the genetic etiology of Alzheimer's disease and related dementias.阿尔茨海默病及相关痴呆症的遗传学病因新见解。
Nat Genet. 2022 Apr;54(4):412-436. doi: 10.1038/s41588-022-01024-z. Epub 2022 Apr 4.
4
Levels of Angiotensin-Converting Enzyme and Apolipoproteins Are Associated with Alzheimer's Disease and Cardiovascular Diseases.血管紧张素转换酶和载脂蛋白水平与阿尔茨海默病和心血管疾病有关。
Cells. 2021 Dec 23;11(1):29. doi: 10.3390/cells11010029.
5
Large-scale integration of the plasma proteome with genetics and disease.血浆蛋白质组与遗传学和疾病的大规模整合。
Nat Genet. 2021 Dec;53(12):1712-1721. doi: 10.1038/s41588-021-00978-w. Epub 2021 Dec 2.
6
Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease.载脂蛋白 B 是阿尔茨海默病中早期 tau 病理学的新型标志物。
Alzheimers Dement. 2022 May;18(5):875-887. doi: 10.1002/alz.12442. Epub 2021 Sep 29.
7
Genetics of 35 blood and urine biomarkers in the UK Biobank.英国生物库中 35 项血液和尿液生物标志物的遗传学研究
Nat Genet. 2021 Feb;53(2):185-194. doi: 10.1038/s41588-020-00757-z. Epub 2021 Jan 18.
8
Heterozygous APOE Christchurch in familial Alzheimer's disease without mutations in other Mendelian genes.载脂蛋白 E 基督城杂合子在其他孟德尔基因无突变的家族性阿尔茨海默病中。
Neuropathol Appl Neurobiol. 2021 Jun;47(4):579-582. doi: 10.1111/nan.12670. Epub 2020 Nov 5.
9
APOE and dementia - resequencing and genotyping in 105,597 individuals.载脂蛋白 E 与痴呆症——在 105597 个人中重测序和基因分型。
Alzheimers Dement. 2020 Dec;16(12):1624-1637. doi: 10.1002/alz.12165. Epub 2020 Aug 18.
10
Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report.载脂蛋白 E3 基督城纯合子对常染色体显性阿尔茨海默病的抗性：一例报告。
Nat Med. 2019 Nov;25(11):1680-1683. doi: 10.1038/s41591-019-0611-3. Epub 2019 Nov 4.
Zotero 插件